Cowie, M.D., Holger Woehrle, M.D., Karl Wegscheider, Ph.D., Christiane Angermann, M.D.D., Ph.D., Erland Erdmann, M.D., Patrick Levy, M.D., Ph.D., Anita K. Simonds, M.D., Virend K. Somers, M.D., Ph.D., Faiez Zannad, M.D., Ph.D., and Helmut Teschler, M.D.: Adaptive Servo-Ventilation for Central Rest Apnea in Systolic Heart Failure Sleep-disordered breathing is certainly common in patients who’ve heart failure with reduced ejection fraction, with reported prevalence rates of 50 to 75 percent.1 Obstructive sleep apnea happens more often in sufferers with heart failure than in the general population.2 The prevalence of central rest apnea increases in parallel with increasing severity of heart failure1 and worsening cardiac dysfunction.3 There are a true number of mechanisms where central sleep apnea may be detrimental to cardiac function, including increased sympathetic nervous system activity and intermittent hypoxemia.4-6 Central sleep apnea can be an independent risk marker for poor prognosis and death in patients with heart failure.4,7,8 In the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Center Failure study, patients with heart failure and central sleep apnea were randomly assigned to receive continuous positive airway pressure or no CPAP.9 The trial was stopped prematurely and didn’t show a beneficial aftereffect of CPAP on morbidity or mortality.10 Adaptive servo-ventilation is certainly a noninvasive ventilatory therapy that effectively alleviates central sleep apnea by delivering servo-controlled inspiratory pressure support along with expiratory positive airway pressure.11,12 The Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Individuals with Heart Failure trial investigated the consequences of adding adaptive servo-ventilation to guideline-based treatment on survival and cardiovascular outcomes in individuals who had heart failure with reduced ejection fraction and predominantly central sleep apnea.The recall totals about 23,000 pounds of food, based on the U.S. Section of Agriculture’s Food Safety and Inspection Service. Expiration dates range from 10/23/13 to 3/17/14 – – a full list of items and UPC codes are available on Reser’s website. Reser’s Fine Foods is based in Beaverton, Ore., however the products in question were produced at a Topeka, Kan. Processing plant. The nagging problem was found out through testing conducted by the Canadian Food Inspection Agency. A traceback investigation and follow-up assessment by FDA at the service determined there is potential cross contamination of items with listeria from product contact surfaces. People who are worried about illness after eating the products should contact their doctor.
Abnormal levels of circulating auto-antibodies within blood of COPD patients Moderate to serious chronic obstructive pulmonary disease could be an auto-immunity problem, relating to researchers in Spain, who studied the presence of auto-antibodies in individuals with COPD and compared them to degrees of control subjects.